MAZIE TRUSTY: Open Payments
NPI 1821307430 · WAYNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$936 in 19 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $936
Food & beverage: $936
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $158 |
| Vanda Pharmaceuticals Inc. | 3 | $151 |
| Alkermes, Inc. | 2 | $143 |
| Axsome Therapeutics, Inc. | 3 | $142 |
| ABBVIE INC. | 2 | $138 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $129 |
| Almatica Pharma LLC | 2 | $32 |
| Validus Pharmaceuticals LLC | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Corium, LLC | 1 | $12 |
Products named: REXULTI, Auvelity, VRAYLAR, FANAPT, CAPLYTA, LYBALVI, LOREEV XR, ARISTADA.
Industry payments across NJ — which companies pay providers there.
